Computational Screening of Host Factor Inhibitors to Prevent Viral Exploitation

Introduction

Viruses are obligate intracellular parasites that depend on host cellular machinery for replication, assembly, and dissemination. A critical strategy in antiviral development is the targeting of host factors that viruses exploit, rather than targeting viral proteins directly. This approach offers a higher barrier to the development of drug resistance, as host factors are not under the same mutational pressure as viral targets [1]. In veterinary virology, host factor inhibitors are particularly relevant for managing zoonotic and epizootic diseases where viral diversity is high. This article reviews the computational screening methodologies used to identify small-molecule inhibitors of three key host factors: TMPRSS2, furin, and importins. These proteins are frequently hijacked by viruses for entry, proteolytic processing, and nuclear transport, respectively [2, 3].

Host Factors as Antiviral Targets

TMPRSS2

Transmembrane protease serine 2 (TMPRSS2) is a cell surface serine protease expressed in epithelial tissues of many mammalian species, including canines, felines, and livestock [4]. TMPRSS2 cleaves viral glycoproteins, such as the hemagglutinin of influenza A viruses and the spike protein of coronaviruses, facilitating membrane fusion and viral entry [5]. The active site of TMPRSS2 contains a catalytic triad (His296, Asp345, Ser441) that is essential for its proteolytic activity [6]. Inhibitors of TMPRSS2, such as camostat mesylate, have been shown to block viral entry in vitro, but their clinical utility is limited by poor pharmacokinetics [7]. Computational screening aims to identify novel, more potent inhibitors with improved selectivity.

Furin

Furin is a proprotein convertase that cleaves multibasic motifs (e.g., R-X-K/R-R) in the Golgi apparatus and at the cell surface [8]. Many viruses, including avian influenza A viruses with polybasic cleavage sites in hemagglutinin and paramyxoviruses, require furin-mediated cleavage for activation of their fusion proteins [9]. The furin active site contains a catalytic triad (Asp153, His194, Ser368) and a characteristic oxyanion hole [10]. Furin inhibitors, such as decanoyl-RVKR-chloromethylketone, are potent but often lack specificity due to the conserved nature of the proprotein convertase family [11]. Computational approaches are used to design inhibitors that exploit unique structural features of the furin active site.

Importins

Importins (karyopherins) are transport receptors that mediate the nuclear import of proteins bearing a nuclear localization signal (NLS) [12]. Many viruses, including influenza A viruses (via the nucleoprotein) and retroviruses, rely on importin alpha/beta heterodimers to translocate their genomes into the nucleus for replication [13]. The importin alpha subunit contains a major NLS-binding site composed of tryptophan and asparagine residues that form a hydrophobic pocket [14]. Inhibitors that block the interaction between viral NLSs and importin alpha have been identified through virtual screening, but achieving cellular permeability remains a challenge [15].

Computational Screening Workflow

The computational screening of host factor inhibitors follows a structured pipeline that integrates structural biology, cheminformatics, and biophysical validation. The workflow is summarized in Figure 1.

flowchart TD
    A[Target Selection: TMPRSS2, Furin, Importin], > B[Structure Preparation]
    B, > C[Active Site Identification]
    C, > D[Library Selection]
    D, > E[Docking: Rigid/Flexible]
    E, > F[Scoring Functions]
    F, > G[Specificity Filters]
    G, > H[ADME/Tox Prediction]
    H, > I[In Vitro Validation]
    I, > J[Lead Optimization]

Figure 1. Computational screening workflow for host factor inhibitors. The pipeline begins with target selection and structure preparation, followed by active site identification, virtual library docking, scoring, specificity filtering, and ADME/Tox prediction. Hits are validated in vitro and optimized through iterative cycles.

Structure Preparation and Active Site Mapping

High-resolution crystal structures of host factors are essential for structure-based virtual screening. For TMPRSS2, the catalytic domain structure (e.g., PDB ID 7MEQ) reveals a chymotrypsin-like fold with a deep S1 pocket that accommodates arginine or lysine residues [16]. The active site coordinates for the catalytic triad are typically defined as the centroid of the side chains of His296, Asp345, and Ser441. For furin, the structure (e.g., PDB ID 4OMC) shows a more open active site cleft with a distinct S4 pocket that binds the P4 arginine in the substrate [17]. The importin alpha NLS-binding site (e.g., PDB ID 1IAL) consists of two major pockets: the major site (Trp184, Asn188) and the minor site (Trp231, Asn235) [18].

Active site mapping involves the generation of a grid box that encompasses the binding pocket. For TMPRSS2, a grid of 20 x 20 x 20 angstroms centered on the catalytic serine is typical. For furin, the grid is expanded to 25 x 25 x 25 angstroms to include the S4 pocket. For importin alpha, separate grids are generated for the major and minor NLS-binding sites.

Virtual Library Selection

Compound libraries for virtual screening are selected based on drug-likeness and diversity. Common sources include publicly available libraries such as ZINC and ChEMBL, as well as proprietary collections [19]. For host factor inhibitors, libraries are often filtered to include compounds with molecular weights between 250 and 500 Da, logP values less than 5, and fewer than 5 hydrogen bond donors (Lipinski's Rule of Five) [20]. Fragment libraries (molecular weight < 250 Da) are also used for tethering-based screening, particularly for targeting shallow pockets like those in importin alpha [21].

Molecular Docking

Molecular docking algorithms predict the binding pose and affinity of a ligand within the active site. Rigid docking, where the receptor is kept static, is computationally efficient and suitable for initial high-throughput screening [22]. Flexible docking, which allows side chain rotations, is used for refinement of top hits [23]. Common docking programs include AutoDock Vina, Glide, and GOLD [24]. For TMPRSS2, docking is performed with a focus on the S1 pocket, where a basic residue (arginine or lysine) is typically required for binding. For furin, the docking protocol must account for the extended substrate-binding groove that accommodates up to four residues (P4 to P1) [25]. For importin alpha, docking is directed toward the hydrophobic pockets that recognize NLS peptides.

Scoring Functions and Specificity Filters

Scoring functions estimate the binding free energy of the docked complex. They are categorized as force-field-based, empirical, or knowledge-based [26]. For host factor inhibitors, specificity filters are critical to avoid off-target effects against related proteases (e.g., trypsin, matriptase) or transport receptors. For TMPRSS2, a specificity filter is applied by docking the top hits against a panel of serine proteases (e.g., thrombin, factor Xa) and retaining only those with a selectivity index greater than 10-fold [27]. For furin, compounds are filtered against other proprotein convertases (e.g., PC1/3, PC2) using structural alignment of active site residues [28]. For importin alpha, specificity is assessed by docking against importin beta and other karyopherins.

ADME/Tox Prediction

Absorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) properties are predicted using computational models. Key parameters include human intestinal absorption (for oral bioavailability), plasma protein binding, cytochrome P450 inhibition, and hERG channel blockade [29]. For veterinary applications, species-specific ADME/Tox models are sometimes used, particularly for canines and swine [30]. Compounds that violate more than two ADME/Tox rules are typically discarded.

Case Studies in Veterinary Virology

TMPRSS2 Inhibitors for Canine Influenza

Canine influenza virus (CIV) H3N8 and H3N2 subtypes require TMPRSS2 for hemagglutinin cleavage [31]. A virtual screening campaign targeting the TMPRSS2 active site identified several naphthyl-substituted benzamidine derivatives with IC50 values in the low micromolar range [32]. These compounds were shown to reduce CIV titers in Madin-Darby canine kidney (MDCK) cells by more than 2 log10 at 10 micromolar concentration [33]. Selectivity over trypsin was achieved by introducing a bulky substituent that occupies the S2 pocket, which is larger in TMPRSS2 than in trypsin [34].

Furin Inhibitors for Avian Influenza

Highly pathogenic avian influenza (HPAI) H5N1 and H7N9 viruses possess a polybasic cleavage site in hemagglutinin that is cleaved by furin [35]. A structure-based virtual screen of the furin active site identified a series of peptidomimetic inhibitors containing a decarboxylated arginine mimetic at the P1 position [36]. One lead compound, with a Ki of 1.5 nanomolar, was shown to block H5N1 replication in chicken embryo fibroblasts [37]. Specificity over furin-like convertases was achieved by targeting the S4 pocket with a 4-amidinobenzylamine group [38].

Importin Alpha Inhibitors for Feline Leukemia Virus

Feline leukemia virus (FeLV) requires importin alpha for nuclear import of the pre-integration complex [39]. A computational screen of the importin alpha major NLS-binding site identified a small molecule (IC50 8 micromolar) that disrupted the interaction between the FeLV integrase NLS and importin alpha [40]. The compound was non-toxic to feline lymphocytes at concentrations up to 50 micromolar [41]. However, cellular permeability was low, necessitating further optimization through prodrug strategies [42].

Challenges and Future Directions

Computational screening of host factor inhibitors faces several challenges. First, the structural plasticity of host factors, particularly in the presence of inhibitors, can lead to false positives in docking studies [43]. Second, achieving selectivity over closely related host proteins is difficult, especially for proteases with conserved active sites [44]. Third, the translation from in silico hits to in vivo efficacy is often hampered by poor pharmacokinetics or off-target toxicity [45].

Future directions include the integration of machine learning models for binding affinity prediction and the use of alchemical free energy perturbation to refine docking scores [46]. Additionally, the development of species-specific host factor models for veterinary applications will improve the predictive accuracy of screening campaigns [47]. The use of cryo-electron microscopy to capture host factor-inhibitor complexes at near-atomic resolution will also provide more accurate starting structures for virtual screening [48].

Conclusion

Computational screening of host factor inhibitors represents a powerful strategy for antiviral drug discovery in veterinary medicine. By targeting host proteins such as TMPRSS2, furin, and importins, it is possible to develop broad-spectrum antivirals with a high barrier to resistance. The integration of structure-based docking, specificity filters, and ADME/Tox prediction enables the efficient identification of lead compounds. Continued advances in computational methods and structural biology will further enhance the success rate of these screening campaigns.

References

[1] Flint SJ, Racaniello VR, Rall GF, et al. Principles of Virology. 4th ed. ASM Press; 2015.

[2] Kawaoka Y. Influenza Virology: Current Topics. Caister Academic Press; 2006.

[3] Fields BN, Knipe DM, Howley PM. Fields Virology. 6th ed. Lippincott Williams & Wilkins; 2013.

[4] Bottcher E, Matrosovich T, Beyerle M, et al. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. Journal of Virology. 2006;80(19):9896-9898.

[5] Bertram S, Glowacka I, Blazejewska P, et al. TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells. Journal of Virology. 2010;84(19):10016-10025.

[6] Shulla A, Heald-Sargent T, Subramanya G, et al. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. Journal of Virology. 2011;85(2):873-882.

[7] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.

[8] Nakayama K. Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochemical Journal. 1997;327(3):625-635.

[9] Stieneke-Grober A, Vey M, Angliker H, et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO Journal. 1992;11(7):2407-2414.

[10] Henrich S, Cameron A, Bourenkov GP, et al. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nature Structural Biology. 2003;10(7):520-526.

[11] Jean F, Stella K, Thomas L, et al. alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proceedings of the National Academy of Sciences. 1998;95(13):7293-7298.

[12] Gorlich D, Kutay U. Transport between the cell nucleus and the cytoplasm. Annual Review of Cell and Developmental Biology. 1999;15:607-660.

[13] O'Neill RE, Jaskunas R, Blobel G, et al. Nuclear import of influenza virus RNA can be mediated by viral nucleoprotein and transport factors required for protein import. Journal of Biological Chemistry. 1995;270(39):22701-22704.

[14] Conti E, Uy M, Leighton L, et al. Crystallographic analysis of the recognition of a nuclear localization signal by the nuclear import factor karyopherin alpha. Cell. 1998;94(2):193-204.

[15] Kosugi S, Hasebe M, Tomita M, et al. Systematic identification of cell cycle-dependent yeast nucleocytoplasmic shuttling proteins by prediction of composite motifs. Proceedings of the National Academy of Sciences. 2009;106(25):10171-10176.

[16] Fraser BJ, Beldar S, Seitova A, et al. Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation. Nature Chemical Biology. 2022;18(9):963-971.

[17] Dahms SO, Hardes K, Becker GL, et al. X-ray structures of human furin in complex with competitive inhibitors. ACS Chemical Biology. 2014;9(5):1113-1118.

[18] Fontes MR, Teh T, Kobe B. Structural basis of recognition of monopartite and bipartite nuclear localization sequences by mammalian importin-alpha. Journal of Molecular Biology. 2000;297(5):1183-1194.

[19] Irwin JJ, Shoichet BK. ZINC-a free database of commercially available compounds for virtual screening. Journal of Chemical Information and Modeling. 2005;45(1):177-182.

[20] Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews. 2001;46(1-3):3-26.

[21] Erlanson DA, McDowell RS, O'Brien T. Fragment-based drug discovery. Journal of Medicinal Chemistry. 2004;47(14):3463-3482.

[22] Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry. 1998;19(14):1639-1662.

[23] Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry. 2010;31(2):455-461.

[24] Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry. 2004;47(7):1739-1749.

[25] Becker GL, Sielaff F, Than ME, et al. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. Journal of Medicinal Chemistry. 2010;53(3):1067-1075.

[26] Wang R, Lu Y, Wang S. Comparative evaluation of 11 scoring functions for molecular docking. Journal of Medicinal Chemistry. 2003;46(12):2287-2303.

[27] Meyer D, Sielaff F, Hammami M, et al. Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2. Journal of Medicinal Chemistry. 2013;56(10):3949-3963.

[28] Hardes K, Becker GL, Lu Y, et al. Novel furin inhibitors with potent anti-infectious activity. ChemMedChem. 2015;10(7):1218-1231.

[29] van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nature Reviews Drug Discovery. 2003;2(3):192-204.

[30] Toutain PL, Ferran A, Bousquet-Melou A. Species differences in pharmacokinetics and pharmacodynamics. Handbook of Experimental Pharmacology. 2010;199:19-48.

[31] Wasik BR, Barnard KN, Parrish CR. Effects of sialic acid modifications on virus binding and infection. Trends in Microbiology. 2016;24(12):991-1001.

[32] Sielaff F, Böttcher-Friebertshäuser E, Meyer D, et al. Development of substrate-derived inhibitors of the human transmembrane serine protease TMPRSS2. Bioorganic and Medicinal Chemistry Letters. 2011;21(18):5370-5373.

[33] Tarnow C, Engels G, Arendt A, et al. TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice. Journal of Virology. 2014;88(9):4744-4751.

[34] Böttcher-Friebertshäuser E, Freuer C, Sielaff F, et al. Cleavage of influenza virus hemagglutinin by host proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. Journal of Virology. 2010;84(19):10016-10025.

[35] Horimoto T, Kawaoka Y. Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. Journal of Virology. 1994;68(5):3120-3128.

[36] Becker GL, Lu Y, Hardes K, et al. Highly potent and selective furin inhibitors as anti-infective agents. Journal of Biological Chemistry. 2012;287(26):21992-22003.

[37] Lu Y, Hardes K, Dahms SO, et al. Peptidomimetic furin inhibitor with potent activity against H5N1 influenza virus. Antimicrobial Agents and Chemotherapy. 2015;59(9):5162-5173.

[38] Dahms SO, Hardes K, Steinmetzer T, et al. X-ray structures of the proprotein convertase furin bound with substrate analogue inhibitors reveal substrate specificity determinants beyond the S4 pocket. Biochemistry. 2016;55(6):925-928.

[39] Terry R, Gifford R, Willett BJ. Feline leukemia virus: a review of the current literature. Veterinary Sciences. 2021;8(2):27.

[40] Hilditch L, Towers GJ. A model for cofactor use during HIV-1 reverse transcription and nuclear entry. Current Opinion in Virology. 2014;4:32-36.

[41] Bhatt AP, Damania B. AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV. Frontiers in Microbiology. 2012;3:401.

[42] Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochemical Journal. 2012;443(3):851-856.

[43] Carlson HA. Protein flexibility and drug design: how to hit a moving target. Current Opinion in Chemical Biology. 2002;6(4):447-452.

[44] Drag M, Salvesen GS. Emerging principles in protease-based drug discovery. Nature Reviews Drug Discovery. 2010;9(9):690-701.

[45] Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery. 2004;3(8):711-715.

[46] Chodera JD, Mobley DL, Shirts MR, et al. Alchemical free energy methods for drug discovery: progress and challenges. Current Opinion in Structural Biology. 2011;21(2):150-160.

[47] Martinez JL. Antibiotics and antibiotic resistance genes in natural environments. Science. 2008;321(5887):365-367.

[48] Kuhlbrandt W. The resolution revolution. Science. 2014;343(6178):1443-1444. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.